L'hospitalet De Llobregat

• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in pa … Recruiting
  2023-505791-30-01 10 2024-04-17 Diabetic Retinopathy
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting
  2023-504865-21-00 5 2024-04-15 Essential Thrombocythemia patients who have an inadequate response to
• Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted a … Recruiting
  2023-508442-18-00 5 2024-04-14 Patients with an infection of the osteosynthesis material implanted af
• A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting
  2023-504374-38-00 5 2024-04-12 Locally advanced cervical cancer
• VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting
  2023-507293-40-00 6 2024-04-11 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl … Recruiting
  2022-500031-37-00 5 2024-04-08 ​ stage IA/IIA Hodgkin lymphoma
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting
  2023-506330-73-00 5 2024-03-13 Advanced (unresectable or metastatic) human epidermal growth receptor
• Phase I/IIa multicentre study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beau … Recruiting
  2024-514544-90-00 9 2024-03-11 Relapsed or refractory B-cell lymphoma
• A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Cas … Recruiting
  2023-505898-32-00 9 2024-02-28 Metastasic Castration-Resistant Prostate Cancer (mCRPC)
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced … Recruiting
  2023-503865-48-00 4 2024-02-16 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced … Recruiting
  2024-517363-24-00 4 2024-02-16 Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian,
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction tre … Recruiting
  2022-502413-29-00 4 2024-01-22 BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal

Showing 385–408 of 1,017 trials